Earning call Transcript Q1 FY 2026-27

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 Date: August 16, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 001. Mumbai - 400 051. Scrip code: 512529 Symbol: VIYASH Dear Sir/Madam, Subject: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Earnings Call Transcript for the quarter ended June 30, 2026 Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Earnings Call Transcript pertaining to the Unaudited Financial Results of the Company for the quarter ended June 30, 2026. The same is also available on the Company’s website at: https://viyash.com/financial This is for your information and appropriate dissemination. Thanking you. Yours faithfully, For Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer “Viyash Scientific Limited Q1 FY’27 Earnings Conference Call” August 12, 2026 MANAGEMENT: DR. HARIBABU BODEPUDI - MANAGING DIRECTOR AND GROUP CHIEF EXECUTIVE OFFICER, VIYASH SCIENTIFIC LIMITED MR. RAJARAM NARAYANAN - EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER, ANIMAL HEALTH, VIYASH SCIENTIFIC LIMITED MR. RAMAKANT SINGANI- CHIEF FINANCIAL OFFICER, VIYASH SCIENTIFIC LIMITED MODERATOR: MR. ABHISHEK SINGHAL – VIYASH SCIENTIFIC LIMITED Page 1 of 17 Viyash Scientific Limited August 12, 2026 Moderator: Ladies and gentlemen, good day and welcome to Viyash Scientific Limited Q1 FY’27 Earnings Conference Call. As a reminder, all participants’ lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing “*” and “0” on your touchtone phone. Please note that this conference is being recorded. I now hand over the conference to Mr. Abhishek Singhal. Thank you and over to you, sir. Abhishek Singhal: Thank you, Pari. A very good evening to all of you and thank you for joining us today for Viyash Scientific Limited Earnings Conference Call for the 1st Quarter of Financial Year 2027. Today, we have with us Dr. Haribabu – Managing Director & Group CEO; Mr. Rajaram – Executive Director and CEO, Animal Health and Mr. Ramakant – CFO of the company, to share the highlights of the business and financials of the quarter. I hope you have gone through our Results Release and the Investor Presentation which have both been uploaded on our website as well as the Stock Exchange. The transcript for this call will be available in a week’s time on the company’s website. Please note that today’s discussion may be forward-looking in nature and must be viewed in relation to the risks pertaining to our business. At the end of this call, in case you have any further questions, please feel free to reach out to the Investor Relations team. I now hand over the call to Dr. Haribabu to make his opening remarks. Haribabu Bodepudi: Thank you, Abhishek. Good afternoon, everyone. Welcome to Viyash Scientific Investor call for Q1 FY’27. Thanks for taking the time to join us today. I am happy to say that Q1 FY’27 is again a very good quarter for us and it shows that [we are] not a one-quarter story, but a company which delivers consistent results quarter after quarter. Our integration is now complete. This will be one of the few successful integrations you can find in the industry and that too in record time period. Starting with the quarter performance: Revenue from operations for Q1 FY’27 was Rs. 946 crores, grown by 20% year-on-year. EBITDA was Rs. 205 crores, grown by 59% year-on-year, with EBITDA margin at 21.6%, expanding by almost 530 basis points over last year. Profit after tax was Rs. 79 crores, which has more than doubled year-on-year. Our EBITDA to PAT conversion is showing good improvement both year-on-year as well as quarter-on-quarter. Page 2 of 17 Viyash Scientific Limited August 12, 2026 Our balance sheet continues to show improvement. Net debt has come down to Rs. 86 crores and net debt to EBITDA is now 0.1x versus 0.24x last quarter, and almost 1x a year back. So, in 4 quarters, we have gone from a leveraged combined entity to a company which is virtually debt- free on a net basis. This gives us tremendous opportunity with respect to brownfield expansion as well as exploring inorganic opportunities. Coming to segment performance: Our Animal Health Formulation business continues to grow very strong across all regions, and we believe the growth will continue with our continuous focus on new product launches, geo- extension for our existing products to other countries, expanding R&D and accelerating new product development. We continue to invest in expanding our manufacturing operations. We are also seeing strong growth in domestic market as well (up 60%), and here we are looking to expand our fieldforce and product portfolio further to grow aggressively. Coming to Human formulation: Our US business has grown 60% showing results of our efforts to moving towards backward- integrated, more complex products. That is now translating into real growth along with profitability improvement. API revenue has been broadly flat quarter-on-quarter due to timing issues on account of raw material price volatility as customers were in wait-and-watch approach. As all you guys know, the war is continuing, nobody knows when it’s going to end. During June, most of the customers wanted to wait and see how it’s going to work out, but now we see good traction, lot of orders are coming back, and I can see this quarter is going to the best quarter for API for us. Coming to where we are investing for growth: We have signed SPA for Bio For Life acquisition in Italy, and we are expecting to close the acquisition in next few months basis fulfillment of certain conditions as per the agreement. This acquisition, as I mentioned on previous call, aligns with our focus on companion Animal Health as number one strategic growth area for the next 5 years. BioForLife gives us direct market access in Italy, one of the largest companion Animal markets in Europe. It comes with a companion Animal portfolio of about 85 products, which can be extended to other core markets, and salesforce with about 85% Vet clinic coverage in Italy, plus strong local talent. Combined with our BI partnership in India, which is now scaling up, our own R&D and manufacturing investments in companion Animals, this is a very meaningful step in building the entire companion animal platform across the world. On Farm Animals: Page 3 of 17 Viyash Scientific Limited August 12, 2026 We are focusing on filling the white spaces in our current portfolio, as well as expanding the market for existing products to other geographies. We want to focus on new product development on molecules which have potential across multiple geographies. For Human Formulations, as I mentioned earlier, we will continue to focus on first-to-file opportunities, with focus more on high-potent complex formulations, with fully backward integration support on key molecules. In API and CDMO focus is on day 1 launch, complex molecules, expanding our CDMO business to create differentiation. We have strong relationships built with innovators across Human as well as Animal Health, strong credentials in manufacturing, which helps us create mutually beneficial partnership models on the CDMO side. So, to summarize: Q1 FY’27 shows continu [Showing first 8,000 characters — download PDF for full document]